The gene expression program mediated by this complex, including downregulation of genes involved in the cytochrome P450 pathway and glutathione metabolism, can promote pancreatic cancer resistance to MEK inhibitors. This evidence concerns the gene MAP2K7 and pancreatic neoplasm.